BioSim™ anti-VEGF-A (Human) ELISA Kit

Ranibizumab (Lucentis®) is a recombinant human IgG1 monoclonal antibody fragment (Fab) that blocks angiogenesis by inhibiting vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, Ranibizumab, has been approved by the FDA for treatment of patients with wet age-related macular degeneration. Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in people over the age of 50 in the developed world. Although an estimated 80% of patients with AMD have the non-neo vascular form, the neo vascular (wet or exudative) form is responsible for almost 90% of severe visual loss resulting from AMD. Currently, the most commonly used VEGF antagonists are ranibizumab (Lucentis, Genentech, Inc.) and Ranibizumab (Avastin; Genentech, Inc.). Ranibizumab, which is an antibody fragment form the Ranibizumab molecule with an increased binding affinity for all forms of VEGF, has been approved for the treatment of patients with neo-vascular AMD by the Food and Drug Administration and by the European Medicines Agency. BioVision’s Ranibizumab ELISA kit is developed for the quantification of Ranibizumab concentration in human serum or plasma with high sensitivity and reproducibility.

Alternate Name: N/A

Tag Line: A Sandwich ELISA kit for the quantitative measurement of Ranibizumad in serum, plasma, culture supernatants and other biological fluids.

Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- quantitative measurement of Ranibizumad in human serum and plasma

Detection Method: Absorbance (450 nm)

Sample Type: Human serum and plasma

Species Reactivity: Human

Applications: Quantitative measurement of Ranibizumad in human serum and plasma

Features & Benefits: Easy, convenient, sensitive and time-saving method to measure the level of Ranibizumad in human serum and plasma. Detection Range: 1.22 – 625 ng/ml